Document is current

Article History

Accepted: 28 September 2023

First Online: 13 October 2023

Declarations

:

: This study was sponsored by GlaxoSmithKline Biologicals SA (Study identifier VEO-000364). Support for third-party writing assistance for this article, provided by Megan Thomas, Costello Medical, UK was funded by GSK in accordance with Good Publication Practice (GPP 2022) guidelines ().

: Substantial contributions to study conception and design: AM, NP, WB, JAG; substantial contributions to analysis and interpretation of the data: AM, NP, WB, JAG; drafting the article or revising it critically for important intellectual content: AM, NP, WB, JAG; final approval of the version of the article to be published: AM, NP, WB, JAG.

: AM and JAG are employed by and hold shares in the GSK group of companies; NP has received contractual fees by GSK, has received grants or contracts from the German Federal Ministry of Education and Research (BMBF) and the PATH Center for Vaccine Innovation and Access, has received support from the Defence Threat Reduction Agency for attending meetings for the Annual Biological Safety Conference, Milwaukee and has participated on the GSK Rotavirus Advisory Board; WB is employed by and owns shares in the GSK group of companies.

: Not applicable.

: Not applicable.

: Not applicable.

: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

: Not applicable.